Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)

This is a prospective, multi-center, randomized, dose escalation study to document the
effects of adventitial delivery of temsirolimus (Torisel) after revascularization of lesions
below the knee in symptomatic patients with critical limb ischemia (CLI). Up to 60 patients
(20 low-dose, 20 high-dose and 20 control) at up to 15 sites in the United States. This study
will assess the safety and effectiveness of Bullfrog Micro-Infusion Device adventitial
deposition of temsirolimus in reducing intimal hyperplasia, inflammatory markers and
composite safety endpoints in patients with clinical evidence of chronic critical limb
ischemia after revascularization of one or more angiographically significant lesion(s) in
below-knee popliteal or tibial vessels.

Inclusion Criteria:

Screening Criteria:

- Age ≥18 years and <90 years

- Patient has been informed of the nature of the study, agrees to participate and has
signed an IRB approved consent form

- Female patients of childbearing potential have a negative pregnancy test ≤7 days
before the procedure and are willing to use a highly effective method of birth control
(See Section 12.2) one month preceding and 12 months following study treatment

- Patient has documented chronic Critical Limb Ischemia (CLI) in the target limb from
the distal segment (P3) of the popliteal artery to the ankle joint prior to the study
procedure with Rutherford Category 3, 4 or 5

- Life expectancy >1 year in the Investigator's opinion

Angiographic Criteria:

- Target vessel(s) diameter ≥2 mm and ≤8 mm

- Single or multiple atherosclerotic lesion(s) ≥70% in at least one below-knee popliteal
or tibial target vessel including the tibioperoneal trunk that totals up to no greater
than 30 cm in length (with no greater than 5 cm length of contiguous intervening
normal artery), with possible extension into the popliteal artery distal to the center
of the knee joint space (the P3 segment)

- Successful revascularization of the TL with less than 30% residual stenosis, run-off
down to the foot and direct in-line flow to any foot wound, if a wound is present at
baseline

Exclusion Criteria:

• Screening Criteria

- Patient is already enrolled in another clinical study of systemic drug therapy or
another device study that has not completed its primary endpoint

- Patient unwilling or unlikely to comply with visit schedule

- Patients who are incapable of providing consent and/or incapable of understanding the
nature, significance and implications of the clinical trial

- Patient is already receiving or planned to receive systemic immunotherapy,
chemotherapy, or steroids (however, inhaled steroids for asthma treatment or topical
steroid uses are allowed)

- Patient has a bilirubin level of >1.5xULN

- Recent (<30 days prior to study procedure) myocardial infarction

- Cerebrovascular accident <60 days prior to the study procedure

- Planned major (above the ankle) target limb amputation

- Active foot infection; however, osteomyelitis in the toes or mild cellulitis around
the perimeter of gangrene or small ulcers (<25mm) are not exclusions, but
osteomyelitis of the metatarsal or more proximal region would be exclusionary

- Inability to receive temsirolimus or iodinated contrast medium due to labeled
contra-indications or known sensitivity reactions Estimated glomerular filtration rate
(eGFR, calculated from serum creatinine using an isotope dilution mass spectrometry
(IDMS)-traceable equation) less than 30 mL/min, except for patients with end stage
renal disease on chronic hemodialysis

- Stage 3 (per SVS WIfI classification) or worse heel ulcers or heel ulcers that are
determined to be primarily neuropathic in nature or non-ischemic in origin

Angiographic/Procedural Criteria

- Hemodynamically significant inflow lesion (≥50% DS) or occlusion in the ipsilateral
iliac, SFA, or popliteal arteries (P1 and P2) in which there is failure to
successfully treat and obtain a <30% residual stenosis post-revascularization, with
bailout stenting as needed (in-flow lesions should be treated prior to treating the
target lesion)

- Target lesion length is >30 cm as measured from proximal normal vessel to distal
normal vessel

- Total length of lesions treated during the case (including target lesion, inflow
lesions, and other non-target lesions) >30 cm

- Use of alternative therapy, e.g. radiation therapy, drug-eluting stents (DES) or
drug-eluting balloon/drug-coated balloons (DEB/DCB) as part of the target lesion
treatment or during the previous 2 months within the target lesion

- Previously implanted stent in the TL(s)

- Aneurysm in the target vessel

- Acute thrombus in the target limb

- Failure to cross the TL with a guide wire; however, subintimal wire crossing is
allowed

- Heavy eccentric or concentric calcification at target lesion, which in the judgment of
the investigator would prevent penetration of the Micro-Infusion Device needle through
the vessel wall